Results 51 to 60 of about 9,215 (199)

α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation

, 2015
Alpha-radioimmunotherapy targeting CD45 may substitute for total body irradiation in hematopoietic cell transplantation (HCT) preparative regimens for lymphoma. Our goal was to optimize the anti-CD45 monoclonal antibody (MAb; CA12.10C12) protein dose for
Frost, Sofia,, Sandmaier, Brenda M, Hamlin, Donald K, Pagel, John M, Storb, Rainer, Bäck, Tom,, Santos, Erlinda B, Knoblaugh, Sue E, Press, Oliver W, Frayo, Shani L, Kenoyer, Aimee L, Wilbur, D Scott, Miller, Brian W   +12 more
core   +1 more source

CD19+Ki67+B cells regulated by NAMPT as key modulators in triple-negative breast cancer with brain metastasis

Breast Cancer Research
Background Among breast cancer subtypes, triple-negative breast cancer (TNBC) stands out for its aggressiveness and high frequency of brain metastases. However, the mechanisms driving BrM remain poorly understood.
Qiyi Zhou, Zhimin zhu, Yuxin Zhao, Di Jing, Liyuan Zhang   +4 more
doaj   +1 more source

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model

Pharmaceuticals, 2022
In this study, we compared the tumor-targeting properties, therapeutic efficacy, and tolerability of the humanized anti-CAIX antibody (hG250) labeled with either the α-emitter actinium-225 (225Ac) or the β--emitter lutetium-177 (177Lu) in mice.
Robin I. J. Merkx, Mark Rijpkema, Gerben M. Franssen, Annemarie Kip, Bart Smeets, Alfred Morgenstern, Frank Bruchertseifer, Eddie Yan, Michael P. Wheatcroft, Egbert Oosterwijk, Peter F. A. Mulders, Sandra Heskamp   +11 more
doaj   +1 more source

Radioimmunotherapy Dosimetry—A Review [PDF]

Acta Oncologica, 1993
Results from therapeutic trials in systemic radiation therapy with radiolabelled monoclonal antibodies are difficult to compare, because of lack of accurate dosimetry. This applies macroscopically as well as microscopically for both tumours and normal tissues.
S E, Strand, B A, Jönsson, M, Ljungberg, J, Tennvall   +3 more
openaire   +2 more sources

Advances in research on layered double hydroxides for biomedical applications

Smart Molecules, EarlyView.
Layered double hydroxides (LDHs) are pH‐responsive nanomaterials with broad biomedical applications. This review summarizes LDH synthesis methods and compares their advantages. It highlights LDHs' progress in cancer therapy, including chemo‐photothermal, chemo‐immunotherapy, and photodynamic‐immunotherapy combinations and their potential in bone repair.
Xinhui Yang, Zhiping Zhang, Zhao Wang, Hao Zhang, Yen Leng Pak, Yingying Jing, Yurong Guo, Fang Li, Xiao Wang, Quanxiang Han, Lei Yu, Xuejiao Li, Xing Gao, Jibin Song   +13 more
wiley   +1 more source

Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network

, 2011
The Radioimmunotherapy Network (RIT-N) is a Web-based, international registry collecting long-term observational data about radioimmunotherapy-treated patients with malignant lymphoma outside randomized clinical studies.
Woijciech Jurczak, Delaloye A. B., Hohloch K., Cacchione, Roberto, Jurczak, W., Delaloye, A.B., Lorenz Trümper, Karin Hohloch, Cheolwon Suh, Suh C., Hohloch, K., Jurczak W., Delaloye, Angelika Bischof, Suh, Cheolwon, Gómez-Codina, J., Gómez Codina J., Truemper, Lorenz H., Windemuth Kieselbach C., Hohloch, Karin, Zinzani, P.L., Werner Linkesch, Pier Luigi Zinzani, Linkesch, Werner, Roberto Cacchione, Gomez-Codina, Jose, Jurczak, Woijciech, Cacchione R., Windemuth-Kieselbach, C., Linkesch, W., Trümper, L., Christiane Windemuth-Kieselbach, Cacchione, R., Angelika Bischof Delaloye, Linkesch W., Jose Gómez-Codina, Windemuth-Kieselbach, Christiane, ZINZANI, PIER LUIGI, Trümper L., Suh, C.   +38 more
core   +1 more source

Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial

Pharmaceuticals, 2015
The first-in-human phase 1 clinical radioimmunotherapy (RIT) trial with 212Pb-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoylmethyl)-cyclododecane-trastuzumab (212Pb-TCMC-trastuzumab) was completed in October 2014 as a joint effort at the University of ...
Diane E. Milenic, Kwamena E. Baidoo, Martin W. Brechbiel   +2 more
doaj   +1 more source

Radioimmunotherapy: recent results and future directions.

, 1996
PURPOSE To review antibody structure, function, and production; suitable radioisotopes for radioimmunotherapy; challenges facing the field; recent clinical results; toxicity; and future directions.
G L DeNardo, R B Wilder, S J DeNardo
core   +1 more source

Improved Quantification of ¹⁸F-FDG PET during ¹³¹I-Rituximab Therapy on Mouse Lymphoma Models after ¹³¹I Prompt Emission Correction

Diagnostics, 2019
18F-FDG Positron Emission Tomography (PET) is used to monitor tumor response to 131I-therapy, but is confounded by prompt emissions (284, 364, 637, and 723 keV) from 131I, particularly in animal PET imaging.
Young Sub Lee, Hee-Joung Kim, Jin Su Kim   +2 more
doaj   +1 more source

High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy

International Journal of Cancer, Volume 159, Issue 9, Page 2314-2327, 1 November 2026.
ABSTRACT Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy with an immunosuppressive tumor microenvironment, and current immunotherapy provides limited benefit. This highlights the need to identify microenvironmental features enabling effective immune responses.
Jiatian Fang, Zilian Wang, Hui Wang, Jianxin Xue, Kai Kang   +4 more
wiley   +1 more source